Heparin: Past, Present, and Future

Author
Oduah, E.; Linhardt, Robert J.; Sharfstein, S.T.
ORCID
https://orcid.org/0000-0003-2219-5833
Thumbnail
View/Open
Other Contributors
Date Issued
2016
Subject
Biology; Chemistry and chemical biology; Chemical and biological engineering; Biomedical engineering
Degree
Terms of Use
CC BY : this license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. Credit must be given to the authors and the original work must be properly cited.; Attribution 3.0 United States
Full Citation
Heparin: Past, Present, and Future, E. Oduah, R. J. Linhardt, S. T. Sharfstein, Pharmaceuticals, 9, 38, 2016.
Metadata
Show full item record
URI
https://hdl.handle.net/20.500.13015/5090; https://doi.org/10.3390/ph9030038
Abstract
Heparin, the most widely used anticoagulant drug in the world today, remains an animal-derived product with the attendant risks of adulteration and contamination. A contamination crisis in 2007-2008 increased the impetus to provide non-animal-derived sources of heparin, produced under cGMP conditions. In addition, recent studies suggest that heparin may have significant antineoplastic activity, separate and distinct from its anticoagulant activity, while other studies indicate a role for heparin in treating inflammation, infertility, and infectious disease. A variety of strategies have been proposed to produce a bioengineered heparin. In this review, we discuss several of these strategies including microbial production, mammalian cell production, and chemoenzymatic modification. We also propose strategies for creating "designer" heparins and heparan-sulfates with various biochemical and physiological properties.;
Description
Pharmaceuticals, 9, 38; Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Department
The Linhardt Research Labs.; The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS);
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Relationships
The Linhardt Research Labs Online Collection; Rensselaer Polytechnic Institute, Troy, NY; https://harc.rpi.edu/;
Access
CC BY — Creative Commons Attribution; A full text version is available in DSpace@RPI; Open Access;
Collections

The following license files are associated with this item:

CC BY — Creative Commons Attribution
Except where otherwise noted, this item's license is described as CC BY — Creative Commons Attribution